Suppr超能文献

唐氏综合征 21 三体脑类器官可分泌阿尔茨海默病相关的可溶性聚集物,可通过单分子荧光和超分辨率显微镜检测到。

Cerebral organoids with chromosome 21 trisomy secrete Alzheimer's disease-related soluble aggregates detectable by single-molecule-fluorescence and super-resolution microscopy.

机构信息

Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, CB2 1EW, UK.

UK Dementia Research Institute at University of Cambridge, Cambridge, CB2 0AH, UK.

出版信息

Mol Psychiatry. 2024 Feb;29(2):369-386. doi: 10.1038/s41380-023-02333-3. Epub 2023 Dec 15.

Abstract

Understanding the role of small, soluble aggregates of beta-amyloid (Aβ) and tau in Alzheimer's disease (AD) is of great importance for the rational design of preventative therapies. Here we report a set of methods for the detection, quantification, and characterisation of soluble aggregates in conditioned media of cerebral organoids derived from human iPSCs with trisomy 21, thus containing an extra copy of the amyloid precursor protein (APP) gene. We detected soluble beta-amyloid (Aβ) and tau aggregates secreted by cerebral organoids from both control and the isogenic trisomy 21 (T21) genotype. We developed a novel method to normalise measurements to the number of live neurons within organoid-conditioned media based on glucose consumption. Thus normalised, T21 organoids produced 2.5-fold more Aβ aggregates with a higher proportion of larger (300-2000 nm) and more fibrillary-shaped aggregates than controls, along with 1.3-fold more soluble phosphorylated tau (pTau) aggregates, increased inflammasome ASC-specks, and a higher level of oxidative stress inducing thioredoxin-interacting protein (TXNIP). Importantly, all this was detectable prior to the appearance of histological amyloid plaques or intraneuronal tau-pathology in organoid slices, demonstrating the feasibility to model the initial pathogenic mechanisms for AD in-vitro using cells from live genetically pre-disposed donors before the onset of clinical disease. Then, using different iPSC clones generated from the same donor at different times in two independent experiments, we tested the reproducibility of findings in organoids. While there were differences in rates of disease progression between the experiments, the disease mechanisms were conserved. Overall, our results show that it is possible to non-invasively follow the development of pathology in organoid models of AD over time, by monitoring changes in the aggregates and proteins in the conditioned media, and open possibilities to study the time-course of the key pathogenic processes taking place.

摘要

了解可溶性β-淀粉样蛋白 (Aβ) 和 tau 小聚体在阿尔茨海默病 (AD) 中的作用对于预防性治疗的合理设计非常重要。在这里,我们报告了一组方法,用于检测、定量和表征源自具有三体 21 的人诱导多能干细胞 (iPSC) 的脑类器官的条件培养基中的可溶性聚集体,从而包含淀粉样前体蛋白 (APP) 基因的额外拷贝。我们检测了来自对照和同源三体 21 (T21) 基因型的脑类器官分泌的可溶性β-淀粉样蛋白 (Aβ) 和 tau 聚集体。我们开发了一种新方法,根据葡萄糖消耗将测量值归一化为类器官条件培养基中活神经元的数量。归一化后,T21 类器官产生的 Aβ 聚集体增加了 2.5 倍,其中更大 (300-2000nm) 和更纤维状的聚集体比例更高,可溶性磷酸化 tau (pTau) 聚集体增加了 1.3 倍,炎症小体 ASC-specks 增加,氧化应激诱导的硫氧还蛋白相互作用蛋白 (TXNIP) 水平升高。重要的是,所有这些在类器官切片中出现组织学淀粉样斑块或神经元内 tau 病理学之前即可检测到,证明了在临床疾病发作之前,使用来自活遗传倾向供体的细胞在体外模拟 AD 的初始致病机制的可行性。然后,使用来自同一供体在两个独立实验中不同时间生成的不同 iPSC 克隆,我们测试了类器官中发现的可重复性。尽管实验之间疾病进展的速度存在差异,但疾病机制是保守的。总体而言,我们的结果表明,通过监测条件培养基中聚集体和蛋白质的变化,有可能在时间上跟踪 AD 类器官模型中病理学的发展,并为研究发生的关键致病过程的时间进程提供可能性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72c5/11116105/6148f3ac05b2/41380_2023_2333_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验